Pharmaceutical companies sometimes agree to deals worth billions for drugs that have never reached the market.
That sounds risky.
It is.
But biotech licensing deals are usually designed so that much of the money is paid only if the drug succeeds.
Novo Nordisk recently agreed to pay China’s Hengrui $300 million upfront for rights to experimental obesity pill HRS-1596, with another $2.3 billion potentially payable through development, regulatory and commercial milestones. The drug is only cleared to begin Phase I trials in China.
That structure shows how pharma companies try to balance enormous upside with enormous uncertainty.
What Is a Biotech Licensing Deal?
A small biotech company may discover a promising drug but lack the money or global infrastructure to develop it alone.
A larger pharmaceutical company can license the drug.
The biotech receives money.
The pharma company receives rights to:
- develop the drug
- run larger clinical trials
- manufacture it
- sell it in agreed markets
Instead of buying the entire company, the larger firm buys access to one promising asset.
Why There Is an Upfront Payment
The upfront payment is guaranteed money.
Hengrui will receive $300 million from Novo regardless of whether the drug eventually succeeds.
This compensates the biotech for giving away valuable development and commercial rights.
But the upfront amount is usually much smaller than the headline deal value.
That limits the buyer’s initial risk.
The structure looks like:
Smaller upfront payment + larger conditional payments
What Are Milestone Payments?
Milestones are paid only when specific goals are reached.
They can include:
- successful clinical trials
- regulatory approval
- first commercial sale
- reaching revenue targets
For example, a deal advertised as worth $2.6 billion does not mean $2.6 billion changes hands immediately.
Most of that value may never be paid if the drug fails.
This is one reason investors should be careful with headline deal values.
Why Royalties Matter
Some licensing agreements also include royalties.
A royalty gives the original biotech company a percentage of future sales.
Imagine:
Drug sales = $5 billion
Royalty = 10%
The biotech could receive:
$500 million per year
This allows the original developer to keep some upside even after licensing away commercial rights.
The exact royalty structure varies from deal to deal.
Why Pharma Buys Experimental Drugs
Drug development is difficult.
A pharmaceutical company cannot rely only on drugs invented inside its own laboratories.
Licensing allows it to add promising external treatments to its pipeline.
This has become increasingly important as large drugmakers face patent expirations and need new products to replace blockbuster revenue. Reuters recently estimated that drugs generating roughly $400 billion of industry revenue could lose patent protection by 2033.
Buying promising external science can sometimes be faster than developing everything internally.
How Expected Value Works
The most useful way to think about an experimental drug is through probability-weighted value.
Suppose a future drug could generate:
$10 billion of economic value
But investors estimate only a:
20% probability of success
A simplified expected value would be:
$10 billion × 20% = $2 billion
That does not mean the drug is worth exactly $2 billion.
But it explains why companies may pay hundreds of millions today for something that has not yet been approved.
The buyer is purchasing a probability of a much larger future payoff.
Why Clinical Stage Matters
Risk usually declines as a drug progresses.
| Stage | Typical Risk |
|---|---|
| Preclinical | Very high |
| Phase I | Very high |
| Phase II | High |
| Phase III | Lower, but still meaningful |
| Approved | Much lower development risk |
Earlier-stage drugs can have greater upside but much greater uncertainty.
Hengrui’s HRS-1596 remains very early in development, which helps explain why most of Novo’s potential payments are conditional rather than upfront.
Expected Return vs Risk
For investors, the key question is not whether the headline deal is large.
It is:
What probability of success is already reflected in the valuation?
A biotech company may rise sharply after signing a licensing agreement.
But risks remain:
- clinical trials can fail
- regulators can reject the drug
- competitors can develop better products
- sales can disappoint
- development can take years
The best licensing structures share those risks between buyer and seller.
The Bottom Line
Biotech licensing deals allow pharmaceutical companies to make large bets without paying the full price upfront.
The structure is usually:
upfront payment → clinical milestones → approval milestones → commercial payments → possible royalties
This aligns payment with success.
For investors, the lesson is equally important:
A drug’s value depends not only on how large the market could become, but on the probability that the drug ever reaches that market.
For more risk analysis, healthcare research and model-driven market tools, sign up to TradingSimuLab and explore Risk Simulation alongside the wider five-model research framework.
SEO Title: Biotech Licensing Deals: Why Pharma Pays Billions for Unapproved Drugs
Slug: biotech-licensing-deals-pharma-drugs
Meta Description: Learn how biotech licensing deals work, including upfront payments, milestones, royalties and clinical risk when pharma companies license experimental drugs.
Primary Keyphrase: biotech licensing deals
Secondary Keyphrases: drug licensing deals, pharma licensing, milestone payments, biotech royalties, clinical trial risk, experimental drugs, pharmaceutical investing, drug development